{"id":55725,"date":"2026-01-28T21:05:02","date_gmt":"2026-01-28T13:05:02","guid":{"rendered":"https:\/\/flcube.com\/?p=55725"},"modified":"2026-01-28T21:05:04","modified_gmt":"2026-01-28T13:05:04","slug":"fda-removes-suicide-warnings-from-glp-1-drugs-after-investigation-finds-no-causal-link","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55725","title":{"rendered":"FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link"},"content":{"rendered":"\n<p>The <strong>U.S. Food and Drug Administration<\/strong> this month requested that <strong>Novo Nordisk<\/strong> and <strong>Eli Lilly<\/strong> remove warnings about suicidal behavior and thoughts from their <strong>GLP\u20111<\/strong> product labels. The directive affects Novo Nordisk\u2019s <strong>Wegovy (semaglutide)<\/strong> and <strong>Saxenda (liraglutide)<\/strong>, as well as Eli Lilly\u2019s <strong>Zepbound (tirzepatide)<\/strong> for long\u2011term weight management.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-action-amp-investigation-timeline\">Regulatory Action &amp; Investigation Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Companies Affected<\/strong><\/td><td>Novo Nordisk, Eli Lilly<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>Wegovy, Saxenda (Novo); Zepbound (Lilly)<\/td><\/tr><tr><td><strong>Action<\/strong><\/td><td>Removal of suicide warning labels<\/td><\/tr><tr><td><strong>Investigation Trigger<\/strong><\/td><td>Reports of suicidal thoughts\/behaviors in GLP\u20111 patients (mid\u20112023)<\/td><\/tr><tr><td><strong>EMA Investigation<\/strong><\/td><td>Initiated July\u202f2023<\/td><\/tr><tr><td><strong>FDA Investigation<\/strong><\/td><td>Initiated January\u202f2024<\/td><\/tr><tr><td><strong>Key Finding<\/strong><\/td><td>No causal link between GLP\u20111 drugs and suicidality<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-amp-analysis\">Clinical Evidence &amp; Analysis<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-meta-analysis-findings\"><strong>Meta\u2011Analysis Findings<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Scope:<\/strong> Analysis of <strong>90+ studies<\/strong> involving nearly <strong>108,000 patients<\/strong> across GLP\u20111 clinical trials<\/li>\n\n\n\n<li><strong>Result:<\/strong> No higher risk of suicidality among GLP\u20111 users<\/li>\n\n\n\n<li><strong>Expanded Review:<\/strong> No evidence of increased psychiatric side effects, including <strong>psychosis, irritability, anxiety, or depression<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-sentinel-system-analysis\"><strong>Sentinel System Analysis<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Database:<\/strong> FDA\u2019s national electronic safety monitoring system<\/li>\n\n\n\n<li><strong>Comparison:<\/strong> GLP\u20111 drugs vs. <strong>SGLT2 inhibitors<\/strong> (another type 2 diabetes treatment)<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Nearly <strong>2.25\u202fmillion patients<\/strong><\/li>\n\n\n\n<li><strong>Result:<\/strong> GLP\u20111 patients did not face additional risk of suicidal thoughts or behaviors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP\u20111 Market Valuation:<\/strong> Global market exceeded <strong>$50\u202fbillion<\/strong> in 2025, projected to reach <strong>$120\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Warning Removal Impact:<\/strong> Eliminates prescribing hesitation among physicians and reduces patient anxiety, potentially boosting adherence rates by <strong>5\u201310%<\/strong><\/li>\n\n\n\n<li><strong>Novo Nordisk:<\/strong> Wegovy revenue projected to benefit from improved label clarity; stock reaction positive on reduced regulatory overhang<\/li>\n\n\n\n<li><strong>Eli Lilly:<\/strong> Zepbound gains competitive parity; label harmonization simplifies marketing and patient education<\/li>\n\n\n\n<li><strong>Psychiatric Safety:<\/strong> Clears path for broader use in patients with mental health comorbidities, a key demographic in obesity treatment<\/li>\n\n\n\n<li><strong>Regulatory Precedent:<\/strong> Sets standard for how FDA evaluates psychiatric safety signals in metabolic drugs, benefiting pipeline candidates<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Label updates expected <strong>Q1\u202f2026<\/strong>; EMA likely to follow FDA lead in Q2\u202f2026<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial expectations, market growth, and regulatory harmonization for GLP\u20111 therapies. Actual results may differ due to competitive dynamics, physician prescribing patterns, and ongoing pharmacovigilance monitoring.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[199,148,86],"class_list":["post-55725","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-eli-lilly","tag-novo-nordisk","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly remove warnings about suicidal behavior and thoughts from their GLP\u20111 product labels. The directive affects Novo Nordisk\u2019s Wegovy (semaglutide) and Saxenda (liraglutide), as well as Eli Lilly\u2019s Zepbound (tirzepatide) for long\u2011term weight management.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55725\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly remove warnings about suicidal behavior and thoughts from their GLP\u20111 product labels. The directive affects Novo Nordisk\u2019s Wegovy (semaglutide) and Saxenda (liraglutide), as well as Eli Lilly\u2019s Zepbound (tirzepatide) for long\u2011term weight management.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55725\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-28T13:05:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-28T13:05:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55725#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55725\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link\",\"datePublished\":\"2026-01-28T13:05:02+00:00\",\"dateModified\":\"2026-01-28T13:05:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55725\"},\"wordCount\":364,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eli Lilly\",\"Novo Nordisk\",\"Obesity\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55725#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55725\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55725\",\"name\":\"FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-28T13:05:02+00:00\",\"dateModified\":\"2026-01-28T13:05:04+00:00\",\"description\":\"The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly remove warnings about suicidal behavior and thoughts from their GLP\u20111 product labels. The directive affects Novo Nordisk\u2019s Wegovy (semaglutide) and Saxenda (liraglutide), as well as Eli Lilly\u2019s Zepbound (tirzepatide) for long\u2011term weight management.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55725#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55725\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55725#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly remove warnings about suicidal behavior and thoughts from their GLP\u20111 product labels. The directive affects Novo Nordisk\u2019s Wegovy (semaglutide) and Saxenda (liraglutide), as well as Eli Lilly\u2019s Zepbound (tirzepatide) for long\u2011term weight management.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55725","og_locale":"en_US","og_type":"article","og_title":"FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link","og_description":"The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly remove warnings about suicidal behavior and thoughts from their GLP\u20111 product labels. The directive affects Novo Nordisk\u2019s Wegovy (semaglutide) and Saxenda (liraglutide), as well as Eli Lilly\u2019s Zepbound (tirzepatide) for long\u2011term weight management.","og_url":"https:\/\/flcube.com\/?p=55725","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-28T13:05:02+00:00","article_modified_time":"2026-01-28T13:05:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55725#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55725"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link","datePublished":"2026-01-28T13:05:02+00:00","dateModified":"2026-01-28T13:05:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55725"},"wordCount":364,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eli Lilly","Novo Nordisk","Obesity"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55725#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55725","url":"https:\/\/flcube.com\/?p=55725","name":"FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-28T13:05:02+00:00","dateModified":"2026-01-28T13:05:04+00:00","description":"The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly remove warnings about suicidal behavior and thoughts from their GLP\u20111 product labels. The directive affects Novo Nordisk\u2019s Wegovy (semaglutide) and Saxenda (liraglutide), as well as Eli Lilly\u2019s Zepbound (tirzepatide) for long\u2011term weight management.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55725#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55725"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55725#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Removes Suicide Warnings from GLP\u20111 Drugs After Investigation Finds No Causal Link"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55725"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55725\/revisions"}],"predecessor-version":[{"id":55727,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55725\/revisions\/55727"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}